Hims & Hers Stock Soars on Strategic Pact with Novo Nordisk

Hims & Hers partners with Novo Nordisk to distribute Ozempic and Wegovy, resolving a patent dispute and fueling a massive stock surge. The deal pivots its GLP-1 strategy.

A single-day surge of 40% is an extraordinary event, even in the volatile telehealth sector. Shares of Hims & Hers Health experienced precisely that following the announcement of a landmark cooperation agreement with Danish pharmaceutical giant Novo Nordisk. The deal simultaneously resolves an ongoing patent dispute, removing a significant overhang that had weighed on the stock.

A Pivot in Strategy for Weight-Loss Medications

The core of the new agreement centers on distribution. Hims & Hers will now offer Novo Nordisk's branded weight-loss medications, Ozempic and Wegovy—both based on the active ingredient semaglutide—through its digital platform. In exchange, the company will cease actively marketing its own compounded GLP-1 preparations. Existing patients on those therapies are to be transitioned to the approved brand-name drugs, where clinically appropriate.

This partnership follows a turbulent history between the two firms. A previous collaboration dissolved after just a few months when Hims & Hers continued to market lower-cost alternative products. At the time, Novo Nordisk criticized a Hims-specific Wegovy formulation as an "unapproved, counterfeit, and untested copy." Hims & Hers withdrew that product two days after intervention by the U.S. Food and Drug Administration (FDA). The new pact represents a second attempt, this time with explicit contractual limitations for the telehealth provider.

Strong Fundamentals Underpin the Move

This strategic shift comes as Hims & Hers reports robust underlying growth. For fiscal year 2025, the company generated revenue of $2.35 billion, representing a 59% year-over-year increase. Its subscriber base surpassed 2.5 million users, supported by a gross margin of 73.8%. International operations expanded by approximately 400%, and management has set a target to achieve over $1 billion in annual international revenue within three years.

Analysts Revise Targets Upward

The market's reaction was immediate and decisive. On Monday, the stock closed at $22.15, marking a 40.7% gain. Trading volume reached 168.1 million shares—roughly 557% above the three-month average. In the subsequent session, the equity advanced a further 5.9% to $23.47.

Several financial institutions responded by raising their price targets. Needham increased its target to $30, while Deutsche Bank set a $28 target alongside a "Hold" rating. Citi established a $24 objective. Bank of America upgraded the stock from "Underperform" to "Neutral," citing the elimination of litigation risk as a key rationale. BMO Capital Markets also noted that the agreement addresses a primary obstacle to growth.

Future Hinges on Successful Patient Transitions

Despite the recent powerful rally, the share price remains approximately 62% below its 52-week high of $70.43. The critical factor for future performance will be the company's ability to migrate a meaningful portion of its subscriber base to the higher-priced branded medications. The scale of this transition will directly influence the future evolution of both revenue mix and profitability margins for Hims & Hers.